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time of surgery 34, 9), both clinically and ultrasonically.
Recurrences and additional venous treatments where
noted.
Results: The Australian National Medical database
indicates 3262 patients have had SFJ valve (with or
without the subterminal valve) repaired using exostents
for varicose veins. Recurrences have occured in 5 (16%)
of the 31 limbs in the valve stented limb. These were
treated with ultrasound guided sclerotherapy. Recurrent
SFJ incompetence was encountered in 4 (13%) patients.
None have required surgical intervention. Two of the
four limbs with incompetence of other venous systems
treated with venous ablation sustained recurrences.
Conclusions: Exostent venous valve repair at the SFJ
can withstand the haemodynamic stresses of a pregnancy.
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Capturing the Visual Impact of Varicose Veins
John Kingsley1, Thomas King2, Elizabeth Orfe2, David
Wright2. 1Alabama Vascular and Vein Center, Vestavia
Hills, AL; 2BTG International Inc, West Conshohocken,
PA
Objectives: Varicose vein (VV) patients suffer not
only from their symptoms but also from appearance. A
standardized method for assessing VV appearance from a
patient and clinician perspective is lacking. A study was
conducted to assess the performance of a clinician-
reported outcome (ClinRO) instrument and a patient-
reported outcome (PRO) instrument developed through
qualitative patient interviews for the evaluation of VV
appearance.
Methods: To assess the patient visible VV appearance
instrument (PA-V3) and an independent expert panel rat-
ing scale (IPR-V3) of standardized photographs, 40 pa-
tients with VVs were recruited at a single site, half of the
patients had treated saphenofemoral junction (SFJ) incom-
petence; the remainder were awaiting treatment. Patients
scored the appearance of their VV on a 0 to 4 “noticeabil-
ity” scale (0 not noticeable to 4 extremely noticeable,
PA-V3); this was repeated after 2 weeks. A physician scored
the VV on a 0 to 4 severity scale at the same visits.
Standardized photographs of the patient’s VV were
scored on a 0 to 4 severity scale (IPR-V3) by a panel of
independent trained expert physicians blinded to treat-
ment status. Measures were compared for reliability and
variability within and between each other and with other
known assessment tools (VEINES-QOL, CIVIQ-2, and
VCSS).
Results: Most patients were female (72%); mean age
was 50.7 years. Test/retest between assessments produced
matches to within 1 score of 87.5% and 100% for PA-V3
and IPR-V3, respectively. Both measures were found to
correlate well with each other (Pearson coefficient0.793)
and with the physician assessment and other standard as-
sessment tools (ranges from 0.758 to 0.881). As expected,
treated patients had notably lower scores for all
instruments.
Conclusions: PA-V3 and IPR-V3 are sensitive and
reproducible measures of VV appearance from the per-
spective of the clinician, the independent expert panel,
and the patient. These tools are suitable for measuring
change in appearance following VV intervention.
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Objectives: Vena cava filter (VCF) insertion is some-
times performed as a secondary procedure during opera-
tions unrelated to treatment of venous thromboembolism
(VTE). This approach has not been characterized and
limited evidence exists to support it.
Methods: VCF insertions were identified within the
2005-2010 American College of Surgeons National Surgi-
cal Quality Improvement (ACS-NSQIP) Participant Use
Datafile. Secondary VCF insertions, performed during
the same anesthetic as a primary procedure unrelated to
VTE treatment, were classified based on primary CPT
codes. Primary CPT codes were then used to compare
overall rates of secondary VCF insertion and postopera-
tive DVT.
Results: 364 patients met the inclusion criteria. Pri-
mary bariatric surgery procedures accounted for the
largest number of VCF insertions (N174) followed by
colon (N41), hepatobiliary (N14), peripheral vascu-
lar (N14), gastric (non-bariatric) (N13), and ampu-
tation (N10) procedures. Rates of VCF utilization
exceeded incidence of postoperative DVT for bariatric
(2.5 vs. 1.6/1000) and endocrine (3.5 vs. 3.0/1000)
procedures.
Conclusions: Secondary VCF insertion may be over-
utilized, particularly in prophylactic scenarios where
DVT risk is low. Further critical evaluation of VCF use is
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warranted, particularly where utilization rates exceed
DVT incidence.
Table.
Procedure category
Primary
cases
(N)
Secondary VCF
utilization rate
(per 1000 cases)
DVT rate
(per 1000
cases)
Bariatric 69,814 2.49 1.58
Colon 108,898 0.38 7.77
Hepatobiliary 87,454 0.16 2.24
Peripheral vascular 22,445 0.62 7.31
Gastric (non-bariatric) 7,972 1.63 7.65
Amputation 6,312 1.58 8.40
Abdominal exploratory 7,811 1.28 13.95
Aortic 7,173 1.25 9.34
Hernia repair 51,520 0.16 1.98
Skin/soft tissue 3,463 2.30 4.90
Endocrine 2,019 3.47 2.97
Esophageal 13,143 0.46 5.25
Small bowel 14,454 0.42 12.94
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Rates of Elastic Compression Stockings Prescription
following Diagnosis of Deep Venous Thrombosis
Ahmed Kayssi, Andrew Petrosoniak, Jeremy Levenstadt,
Naomi Eisenberg, Graham Roche-Nagle. Department of
Vascular Surgery, Toronto General Hospital, Toronto,
ON, Canada
Objectives: The post thrombotic syndrome (PTS) is a
chronic condition that develops in 20% to 50% of patients
after deep venous thrombosis (DVT). It is characterized by
chronic pain, swelling and heaviness, and may result in
ulceration. Elastic compression stockings (ECS) worn daily
after DVT have been shown to reduce the incidence and
severity of PTS. The aim of our study was to investigate
practices and perceptions of physicians regarding adjunct
therapies to anticoagulation in patients diagnosed with
lover extremity DVT.
Methods: An online survey was conducted of Cana-
dian primary care staff physicians and residents (n685) to
investigate their attitudes towards prescription of ECS post
diagnosis of DVT.
Results: The results demonstrated that the majority of
staff physicians (58%) and residents (58%) were unsure
whether ECS were effective in preventing PTS and in
managing venous symptoms. This resulted in only 12% of
staff physicians and 26% of residents routinely prescribing
ECS for below-knee DVTs. Only 10% of staff physicians
and 12% of residents routinely prescribed ECS for above-
knee DVTs. More than 70% of respondents were unsure
about the optimal timing of initiation of ECS and duration
of therapy. A majority of staff and resident respondents
correctly predicted two out of the top three reasons for
patient non-compliance (soreness and the need for assis-
tance, but not cosmesis).
Conclusions: Daily use of graduated ECS after DVT
appears to reduce the risk of PTS. Our results demonstrate
that there is a lack of consensus among medics regarding
ECS use after DVT. There is a need for widespread educa-
tion regarding the latest evidence of the benefit of ECS
after DVT.
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Rare Incidence of Pulmonary Embolism following Up-
per Extremity DVT (UEDVT) Suggests Role for More
Selective Anticoagulation
Mark M. Levy, Francisco C. Albuquerque, Michael F.
Amendola, Derek R. Brinster, John Pfeifer. Surgery, Vir-
gina Commonwealth University, Richmond, VA
Objectives: Current Chest guidelines counsel at least 3
months of anticoagulation (AC) to treat UEDVTs, yet are
not consistently followed among fragile patients. We
sought to correlate AC use with DVT characteristics and
patient outcomes.
Methods: Four hundred consecutive UEDVT patients
were identified between 2005 and 2009 from our Vascular
Lab Registry. Sonographic and patient characteristics, AC
treatment, PE incidence, mortality and hemorrhagic com-
plications were reviewed.
Results: Among the 400 patients, UEDVT was docu-
mented in the distal innominate (n91), internal jugular
(n 192), subclavian (n 211), axillary (n 146), and
brachial veins (n125). Most were symptomatic (n350,
88%), with sonographically acute appearance (n335,
84%). Many patients had documented malignancy
(n153, 38%), or associated central venous lines (n323,
81%), and most were treated with heparin and/or warfarin.
(n207, 52%). Thirteen patients (3%) suffered PE in asso-
ciation with their UEDVT diagnosis. There was no PE-
related mortality. Following discharge, 4 patients treated
with warfarin died from intracranial hemorrhage. Five ad-
ditional patients required hospital readmission for AC-
related intracranial, GI, and stomal hemorrhage.
Conclusions:AC ismost commonly used to treat more
extensive acute DVT components in younger patients with
better short-term survival. The incidence of PE does not
appear to be improved by AC treatment. Given the ob-
served morbidity and mortality associated with AC, and the
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